Onconova Announces Upcoming Presentations Related to Advanced Rigosertib Clinical Trials at 2016 ASCO Annual Meeting

On May 31, 2016 Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, reported details relating to two poster presentations at the upcoming 2016 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting taking place June 3-7 in Chicago, Illinois (Press release, Onconova, MAY 31, 2016, View Source [SID:1234512903]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Rationale and Mechanism of Action for Rigosertib/Azacitidine Combination Therapy

Poster Presentation with Discussion*
Abstract Number: 7020
Title: Rigosertib (RIG) in combination with azacitidine (AZA) to modulate epigenetic effects and to overcome clinical resistance to hypomethylating agents (HMA) in myelodysplastic syndromes (MDS).
Session Name: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Date: Monday, June 6, 2016
Time and Location: 8:00 AM — 11:30 AM, McCormick Place, Hall A
Presenter: Pratima Chaurasia, PhD, Icahn School of Medicine at Mount Sinai

*Poster discussion session on Monday, June 6, 2016 from 11:30 AM — 12:45 PM

Design of Phase 3 INSPIRE Trial for Second-line Higher-risk Myelodysplastic Syndromes

Poster Presentation
Abstract Number: TPS7077
Title: INSPIRE: A randomized phase III trial of intravenous rigosertib in patients with higher-risk myelodysplastic syndromes (HR-MDS) after failure of hypomethylating agents (HMAs)—Study design informed by subgroup analyses of ONTIME.
Session Name: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Date: Monday, June 6, 2016
Time and Location: 8:00 AM — 11:30 AM, McCormick Place, Hall A
Presenter: Guillermo Garcia-Manero, MD, MD Anderson Cancer Center, Houston, TX